Testing of Residual Host Cell DNA: Importance in Quality Management of Biologicals
Residual host cell DNA testing is an important part of quality control in the manufacturing of biologics. It helps manufacturers monitor process-related impurities, support batch release and demonstrate that residual DNA from the production cell system is controlled at an acceptable level
1. Background: Why residual host cell DNA testing is critical for biopharmaceuticals
Residual DNA arises during the production of biopharmaceuticals when animal, bacterial, or human host cells are used to produce recombinant proteins, monoclonal antibodies, or vaccines. In these manufacturing processes, host cells are typically lysed to extract the desired therapeutic proteins. Despite extensive purification steps, small amounts of host cell DNA may remain in the final product. This residual DNA can be considered a contamination that may compromise both product quality and patient safety.
2. Why is residual DNA a problem?
Residual DNA in biologics presents various risks:
• Immunogenic reactions:Residual DNA may activate the patient's immune system, leading to inflammation, allergic reactions, or even more severe immune responses.
• Oncogenic potential:Host cell DNA may contain oncogenes, which have the potential to cause cancer.
• Infectivity:In rare cases, residual DNA may originate from viral particles or other infectious agents, potentially leading to disease transmission.
3. Common host cell systems in biopharmaceutical manufacturing
The host cell system used during manufacturing determines which residual DNA assay is required.
| Host cell system |
Typical application |
Residual DNA testing relevance |
|---|
| CHO cells |
Recombinant proteins, monoclonal antibodies, complex biologics |
One of the most common mammalian production platforms; residual CHO DNA must be controlled during QC |
| E. coli |
Bacterial expression systems, recombinant proteins, selected vaccines |
Requires host-specific detection of residual bacterial DNA |
| HEK-293 cells |
Viral vectors, vaccines, proteins, CGT-related workflows |
Requires sensitive detection of residual human cell line DNA in HEK-293-based processes |
Different biological products are manufactured using different host cell systems. The analytical method used for residual DNA testing should therefore match the production system.
CHO cells
Chinese Hamster Ovary cells, commonly known as CHO cells, are among the most widely used mammalian cell lines in biopharmaceutical manufacturing. They are frequently used for recombinant proteins, monoclonal antibodies, and other complex biologics. Because CHO-based production is so common, CHO residual DNA testing is an important part of quality control for many biopharmaceutical processes.
E. coli
E. coli is a bacterial expression system widely used for the production of recombinant proteins and other biological products. Bacterial production systems can be efficient and well established, but they require specific testing strategies for residual E. coli DNA in the final product or relevant process samples.
HEK-293 cells
HEK-293 cells are human-derived cells commonly used in biopharmaceutical research and production, especially in applications involving viral vectors, vaccines, proteins, and cell and gene therapy-related workflows. For HEK-293-based processes, sensitive and specific detection of residual HEK-293 DNA is required.
4. Regulatory requirements for residual host cell DNA testing: guidelines an
d limits
Photo: Pexels.com | Thirdman
Major global regulatory authorities, such as the WHO, FDA, and the European Pharmacopoeia, have established strict limits on the amount of residual DNA in biologics to ensure patient safety.
• WHO:Recommends that the residual DNA content in the final product should be less than 10 ng per dose.
• FDA:Sets a limit of 10 ng per dose for biopharmaceuticals, with stricter requirements for vaccines (e.g., Hepatitis A: 100 pg per dose).
• European Pharmacopoeia:Establishes a threshold of 10 ng per dose for most biopharmaceuticals, with even more stringent limits for specific vaccines.
These limits are considered safe and are intended to minimize the potential risks associated with residual DNA.
5. Methods for detecting and quantification of residual host cell DNA
qPCR
Quantitative PCR is widely used for residual DNA testing. It is sensitive and specific, but typically requires a standard curve for quantification. qPCR remains a common method in many established quality control workflows.
dPCR
Digital PCR enables absolute quantification of DNA molecules without the need for a standard curve. This makes dPCR particularly useful for residual DNA testing, especially when precise quantification of low DNA concentrations is required
Digital PCR enables absolute quantification of DNA molecules without the need for a standard curve. This makes dPCR particularly useful for residual DNA testing, especially when precise quantification of low DNA concentrations is required.
Other methods
Other approaches, such as DNA probe hybridization, fluorescence staining, or immunoassay-based methods, may be used in specific contexts. However, molecular methods such as qPCR and dPCR are commonly preferred when high sensitivity, specificity, and quantitative results are required.
6. Importance of fast and accurate testing
Residual host cell DNA can be present at very low levels and may be highly fragmented due to purification, nuclease treatment, or other process conditions. A robust residual DNA assay should therefore be able to detect degraded DNA reliably and provide quantitative results that support decision-making in quality control.
Fast and accurate testing can help manufacturers:
• monitor purification efficiency,
• support batch release,
• confirm compliance with internal and regulatory limits,
• reduce the risk of delays during product release,
• optimize manufacturing and cleaning processes.
Digital PCR can support these needs by enabling absolute quantification and precise detection of residual host cell DNA in relevant sample matrices
7. MiQuant® Residual DNA - dPCR assays for CHO, E. coli and HEK-293
To support residual host cell DNA testing in different production systems, Minerva Biolabs offers MiQuant® Residual DNA - dPCR assays for CHO, E. coli and HEK-293. The assays are designed for the quantitative detection of residual host cell DNA in biological and pharmaceutical matrices and support direct sample testing where matrix compatibility is given
Key features of the MiQuant® Residual DNA - dPCR assays:
• Platform open:Compatible with all major commercial dPCR devices such as QIAcuity®, ddPCR™, and QuantStudio™ Absolute Q™.
• Efficient workflow:Direct sample analysis without prior DNA extraction, simplifying and accelerating the process.
• Stability and handling:Lyophilized kit components facilitate transport and storage.
• Absolute quantification:A major advantage is the absolute quantification of samples without the need for a standard curve.
• Regulatory compliance:Meets the criteria set by EP, WHO, and FDA for residual DNA analysis.
• Validation report available:The validation study was conducted using the QIAcuity® 26k nanoplate.
| |
MiQuant® Residual DNA
CHO - dPCR |
MiQuant® Residual DNA
E. coli – dPCR |
MiQuant® Residual DNA
HEK-293 - dPCR |
|---|
|
 |
 |
 |
| Application |
CHO-based biologics, e.g. recombinant proteins and antibodies |
Bacterial expression systems, proteins and vaccines |
HEK-293-based products, e.g. viral vectors, proteins and vaccines |
| Limit of detection |
0.04 fg/µl |
0.13 fg/µl |
1.7 fg/µl |
| Limit of quantification |
≥0.33 fg/µl |
1 fg/µl |
≥5 fg/µl |
| Specificity |
No cross-reactivity detected |